Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial

This study evaluated 6-month effectiveness and safety of automated insulin delivery (AID) in comparison with multiple daily injections (MDI) in pediatric and adult type 1 diabetes (T1D).

International guidelines endorse automated insulin delivery (AID) as the standard of care for adults and children with type 1 diabetes (T1D), with evidence from systematic reviews showing superior glycemic outcomes compared with MDI or CSII, including improved HbA1c and time in range without increased hypoglycemia. The Medtronic MiniMed™ 670G, the first approved AID system, and its successor, the Bluetooth‑enabled 770G, use the same adaptive algorithm to automate basal insulin delivery; prior trials have shown their safety and efficacy versus CSII. Building on this evidence, the present study reports results from a parallel randomized controlled trial comparing MM670G/770G AID with MDI, with or without CGM, in pediatric and adult T1D populations.